Fisher Asset Management LLC Lowers Stake in Viridian Therapeutics, Inc. $VRDN

Fisher Asset Management LLC cut its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 5.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 509,959 shares of the company’s stock after selling 27,065 shares during the quarter. Fisher Asset Management LLC owned about 0.62% of Viridian Therapeutics worth $7,129,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Y Intercept Hong Kong Ltd bought a new stake in Viridian Therapeutics during the second quarter valued at about $170,000. Creative Planning purchased a new stake in Viridian Therapeutics in the second quarter valued at approximately $179,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Viridian Therapeutics in the 2nd quarter worth approximately $180,000. Envestnet Asset Management Inc. acquired a new position in Viridian Therapeutics in the 2nd quarter worth approximately $187,000. Finally, EntryPoint Capital LLC purchased a new position in Viridian Therapeutics during the 1st quarter worth approximately $185,000.

Viridian Therapeutics Trading Up 3.7%

Shares of VRDN stock opened at $32.46 on Friday. Viridian Therapeutics, Inc. has a fifty-two week low of $9.90 and a fifty-two week high of $33.34. The company has a debt-to-equity ratio of 0.07, a quick ratio of 11.28 and a current ratio of 11.28. The stock’s fifty day moving average is $25.47 and its two-hundred day moving average is $19.77. The firm has a market capitalization of $3.10 billion, a P/E ratio of -10.75 and a beta of 0.87.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Wednesday, November 5th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.48. The business had revenue of $70.57 million during the quarter, compared to analysts’ expectations of $16.21 million. Viridian Therapeutics had a negative net margin of 426.58% and a negative return on equity of 78.50%. Viridian Therapeutics’s revenue for the quarter was up 81993.0% compared to the same quarter last year. Research analysts expect that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Truist Financial set a $41.00 price target on Viridian Therapeutics in a research report on Monday, November 24th. The Goldman Sachs Group reiterated a “buy” rating and set a $40.00 target price on shares of Viridian Therapeutics in a research report on Thursday, November 6th. Oppenheimer boosted their price target on shares of Viridian Therapeutics from $32.00 to $36.00 and gave the stock an “outperform” rating in a report on Tuesday, October 21st. Wall Street Zen upgraded shares of Viridian Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Royal Bank Of Canada lifted their target price on shares of Viridian Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.55.

Insider Buying and Selling

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc acquired 454,545 shares of the business’s stock in a transaction on Thursday, October 23rd. The stock was bought at an average price of $22.00 per share, for a total transaction of $9,999,990.00. Following the acquisition, the director owned 3,914,458 shares in the company, valued at approximately $86,118,076. The trade was a 13.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 1.58% of the company’s stock.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.